ArticleJournal of cellular and molecular medicine2025
VHL-Mediated SYT11 Degradation Suppresses Gastric Cancer Cell Growth and Invasion Through Downregulation of SPINK1.
Article in Journal of cellular and molecular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- VHL-Mediated SYT11 Degradation Suppresses Gastric Cancer Cell Growth and Invasion Through Downregulation of SPINK1.Journal of cellular and molecular medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The ubiquitin-proteasome system is a post-translational modification pathway that plays a critical role in regulating cell survival and death. E3 ubiquitin ligases are key tumour regulators and potential therapeutic targets in gastric cancer. This study investigates whether von Hippel-Lindau (VHL), an E3 ligase, regulates the stability of synaptotagmin 11 (SYT11) protein in gastric cancer cells. VHL overexpression decreased SYT11 protein expression without affecting SYT11 mRNA expression. Notably, VHL overexpression decreased the half-life of SYT11 protein, and MG132, a proteasome inhibitor, reversed SYT11 degradation by VHL. Immunoprecipitation confirmed the binding of SYT11 to VHL, and VHL knockdown resulted in reduced SYT11 ubiquitination and degradation. Transcriptome sequencing revealed the downregulation of serine peptidase inhibitor kazal type 1 (SPINK1) by VHL and its upregulation by SYT11. VHL downregulated the expression of SYT11, which subsequently led to the inhibition of SPINK1 expression. Furthermore, SPINK1 knockdown inhibited the growth and invasion of gastric cancer cells, mirroring VHL overexpression effects. The inhibition of growth and invasion in MKN1 and SNU484 cells by VHL was rescued by the overexpression of SYT11 and SPINK1. These findings demonstrate that the proteasome-dependent degradation of SYT11 by VHL and the subsequent reduction in SPINK1 expression inhibit gastric cancer cell growth and invasion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.